MolecularPathology.ca

 
Faculty Toronto

University of Toronto and University Health Network

Ming Tsao, MD


Professor of Laboratory Medicine and Pathobiology (Director of Training Program)

As a Consultant Surgical Pathologist and Senior Scientist, Dr. Tsao's primary research interest has focused on the role of tyrosine kinase receptor signaling cascades in the pathogenesis and biology of lung and pancreatic cancers, and their potential roles as prognostic factors and molecular targets of novel therapeutic strategies. His laboratory routinely uses a wide range of molecular and cell biological techniques, including high throughput array techniques, mutational analysis, laser capture micro-dissection, real-time PCR, in vitro expression systems and animal models of human cancer.

 


David Hedley, MD, PhD

 

Professor of Medicine (OCI/PMH Site Director of Training Program)

As a Clinician Scientist and Medical Oncologist, Dr. Hedley's research goal is the rational development of molecular targeted therapeutics, based on improved understanding of cancer biology. His group is recognized internationally for its work on the development and application of advanced methodology based on the use of flow cytometry and digital fluorescence microscopy. The main areas of his current research are to understand how the solid tumour microenvironment influences treatment sensitivity via effects on hypoxia- and redox-sensitive transcription factors, and the development of molecular targeted therapeutics. This work focuses on carcinomas of the uterine cervix and pancreas, and places particular emphasis on the use of xenograft models and biopsy samples obtained from patients. Dr Hedley brings to the program technical expertise in single cell analysis, and the perspective of a practicing oncologist actively researching laboratory correlates of molecular targeted cancer therapy.

 


Sylvia Asa, MD, PhD

Professor of Laboratory Medicine and Pathobiology (Pathologist-in-Chief, UHN)

As an internationally-recognised expert in endocrine pathology and a Clinician-Scientist, Dr. Asa's research focus is on identifying mechanisms of endocrine tumorigenesis that can then be translated into novel diagnostic methods. Her analyses employ multiple molecular techniques applied to primary human tumors in vitro and in vivo and using mouse models.

 


 



Suzanne Kamel-Reid, PhD

Professor of Laboratory Medicine and Pathobiology

As the Director of Molecular Diagnostics at the University Health Network, Dr. Kamel-Reid has trained several residents and fellows in hematology, pathology and otolaryngology, and is also active in the teaching and education of trainees studying to become molecular genetics laboratory technologists. She is involved in the genetic testing and reporting of over 3000 patient samples per year, with a focus on the diagnosis, prognosis and monitoring of disease using genetic markers. Dr. Kamel-Reid brings to the program expertise in translational research, the development of molecular diagnostic techniques using advanced methodologies and equipment, and implementation of these technologies in a hospital pathology department setting.


 

 

 

Susan J. Done, MA(Cantab), MB, BChir, PhD, MBA

Associate Professor, Departments of Laboratory Medicine and Pathobiology and Medical Biophysics

As a Consultant Surgical Pathologist and Scientist, Dr. Done's research is focused around the identification and characterization of molecular events in the development of human solid tumors with an emphasis on breast cancer. Major questions in the lab address the molecular events necessary for the transition from pre-invasive to invasive breast cancer and development of the first metastatic deposit. Similar issues are also being studied in ovarian and prostate cancer. Research is primarily translational employing many molecular biology and pathology techniques including: laser capture microdissection, image analysis, high throughput microarray analysis of DNA and RNA, chromosomal CGH, FISH, quantitative PCR and RT-PCR and a variety of PCR based mutational analyses.


Li Zhang, MD, PhD 

Professor of Departments of Laboratory Medicine and Pathobiology, Immunology

As a Senior Scientist and a Clinical Research Chair in Transplantation, Dr. Zhang is an internationally recognized transplantation immunologist. The major research interests of her group are: 1) to develop novel immunological approaches for the prevention, diagnosis, and treatment of graft rejection, graft versus host disease, autoimmune and malignant diseases; and 2) to understand the cellular and molecular mechanisms involved in controlling these diseases in animal models through immune regulation by using various modern techniques.

  

Michael Moran, PhD

Professor of Molecular and Medical Genetics and Banting and Best Department of Medical Research

Dr. Moran is a Senior Scientist and member of the Comprehensive Cancer Centre at the Hospital for Sick Children, and Director of the Drug Discovery Program at the McLaughlin Centre for Molecular Medicine, located at UHN, MARS.  He holds the Tier-1 Canada Research Chair in Molecular Therapeutics.  He was co-founder of the company MDS Proteomics and let several collaborative research projects in drug discovery that were partnered with pharmaceutical companies.  His research focus includes the development and application of quantitive proteomics methods involving mass spectrometry and bioinformatics in order to identify and quantify phosphorylation-mediated signaling networks in human tumors and preclinical models.  The objectives of these studies include the identification and validation of new drug targets; the determination drug mechanisms of action; and the stratification of tumors according to their protein phosphosylation signatures. 

 

Michael Moran's Website:  http://www.sickkids.ca/AboutSickKids/Directory/People/M/Michael-Moran%20.html

 

 

Thomas Kislinger, PhD

Associate Professor of Department of Medical Biophysics

Thomas Kislinger is a Scientist at the Division of Cancer Genomics and Proteomic at the Ontario Cancer Institute, and the Assistant Professor at the Department of Medical Biophysics.  His laboratory develops and applies powerful tools of proteomics and bioinformatics and allied computational tools.  As the Canada Research Chair in Proteomics and Cancer Research at the University of Toronto, Dr. Kislinger is currently focusing on optimizing technologies that allow for sensitive and selective isolation and characterization of surface proteins from cell culture (in vitro) or directly from the surface of microvascular endothelial cells (in vivo).  He is using application of protein identification technology (MudPIT), a powerful peptide separation technology.  Additionally, his interests lie in dynamics of protein-protein interactions by using TAP-tagging in combination with mass spectrometry.  Cancer related questions are aimed at the discovery and validation of novel biomarkers.  Dr. Kislinger is working in developing and applying modern bioinformatics tools to the analysis and annotation of the generated datasets, and will be actively working to make a better biological use of mass spectrometry derived proteomics data.

 

Thomas Kislinger's Website:  http://medbio.utoronto.ca/faculty/kislinger.html

 

 

Geoffrey Liu, MD FRCPC

Associate Professor in the Department of Medical Oncology

Dr. Liu is the Alan B. Brown Chair in Molecular Genomics at Princess Margaret Hospital, University of Toronto and a CCO Chair in Experimental Therapeutics and Population Studies. He is also a molecular epidemiologist and pharmacogenetics expert. Dr. Liu's research is focused on evaluating the genetics basis of drug response and toxicity in oncology. He also has expertise in blood-based bio-repositories and is involved in numerous studies of the role of genetic polymorphisms in cancer risk screening, prognoses and therapy. His clinical focus is on head and neck, lung, esophageal and other GI cancers, mesotheliomas and thymomas.

Geoffrey Liu's Websites and Publications:

http://www.uhnresearch.ca/researchers/profile.php?lookup=12092
http://medbio.utoronto.ca/faculty/liu_geoff.html

 

 

Richard (Dick) P. Hill, PhD

Professor in the Departments of Medical Biophysics and Radiation Oncology Senior Scientist, Ontario Cancer Institute

Dr. Hill is internationally recognized leader in the field of laboratory and translational research studies in tumour and normal tissue radiobiology, metastasis and aspects of the tumour microenvironment, notably hypoxia. He has received international honours including the National Cancer Institute of Canada 2007 Robert L. Noble Prize. His work is respected for creativity, detail, and high relevance to cancer treatment. He is an educator and is co-editor of a textbook internationally used to teach radiobiology to oncology trainees.

Richard Hill’s Website and Publications:

http://www.uhnresearch.ca/researchers/profile.php?lookup=2445

 

 

Igor Jurisica, PhD

Associate Professor, Departments of Computer Science and Medical Biophysics, University of Toronto
Senior Scientist, Division of Signaling Biology, Ontario Cancer Institute (OCI)
Adjunct Professor, School of Computing, Queen's University, Kingston, ON

Dr. Jurisica is an IBM Centre for Advanced Studies Visiting Scientist and a world leader in integrative computational biology, and representation, analysis and visualization of high dimensional data generated by high-throughput biology experiments. He holds a Tier II Canada Research Chair in Integrative Computational Biology. Further, his collaboration with members of the Molecular Oncologic Training Program involves studying the lung cancer genome and proteome to identify prognostic and predictive expression signatures and novel therapeutics targets. Combining comprehensive analyses with known and predicted secreted proteins he works on identifying novel biomarkers for early detection of ovarian cancer.

Igor Jurisica’s Website and Publications:

http://www.cs.utoronto.ca/~juris

 

 

Gilda da cunha Santos, MD, PhD

Associate Professor at Laboratory Medicine and Pathobiology

Dr. Santos expertise extends to clinical cytopathology over 15 years. Her current interest is to develop and improve "in situ" hybridization technologies for expanding the spectrum of the application in cancer prevention, diagnosis, prognosis and therapy selection. Within next years her focus will be on identifying biomarkers using cytological materials.

 

 

 

 

 

 

Andrew Evans, MD, PhD

Staff Pathologist and Associate Professor of Laboratory Medicine and Pathobiology

Dr. Evans is a Consultant Surgical Pathologist and Clinician Scientist with a subspecialty interest in the molecular pathology of urological malignancies, prostate and kidney cancer in particular. His current research focuses primarily on the role of PTEN abnormalities and TMPRSS2-ERG gene re-arrangements in the development and progression of prostate cancer. These studies are based the use of highly annotated tissue microarrays and fluorescence in-situ hybridization (FISH) to study tissue samples obtained from well-characterized patient cohorts at University Health Network.

 

 

Last Updated ( Wednesday, 02 February 2010 )